Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

被引：8
|
作者：
Fushimi, Chihiro [1 ]
Baba, Daisuke [1 ]
Masubuchi, Tatsuo [1 ]
Yamazaki, Morio [1 ]
Kitani, Yosuke [1 ]
Kitajima, Tatsuya [1 ]
Tanaka, Junpei [1 ]
Hanyu, Kenji [1 ]
Tanaka, Naruhisa [1 ]
Miura, Kouki [1 ]
Tada, Yuichiro [1 ]
机构：
[1] Int Univ Hlth & Welf, Dept Head & Neck Oncol & Surg, Mita Hosp, Tokyo, Japan
来源：
IN VIVO | 2020年 / 34卷 / 05期
关键词：
Head and neck squamous cell carcinoma; paclitaxel; cetuximab; recurrent; metastasis; PLATINUM-BASED CHEMOTHERAPY; RECURRENT/METASTATIC HEAD; PLUS CETUXIMAB; COMBINATION; FAILURE; CANCER;
D O I：
10.21873/invivo.12084
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Background/Aim: Head and neck cancers account for 8% of all cancer cases worldwide. However, identifying the optimal treatment for recurrent or metastatic head and neck cancer (R/MHNSCC) has been challenging. The aim of this study was to evaluate the efficacy, safety, and prognostic factors of the outcome of patients with R/MHNSCC who were treated with weekly cetuximab and paclitaxel (Cmab-PTX). Patients and Methods: The records of R/MHNSCC patients who were treated with Cmab-PTX in our institution between June 2013 and September 2017 were collected. We analyzed Overall survival (OS), progression-free survival (PFS), prognostic factors and adverse events. Results: The records of 59 patients treated with Cmab-PTX were analyzed. The median PFS was 5.7 months, and the median OS was 11.8 months. Patients who had been administered cetuximab previously had shorter PFS and OS than those who had not. Conclusion: Cmab-PTX may be considered as a treatment option in head and neck R/MHNSCC patients.
引用
收藏
页码：2653 / 2657
页数：5
相关论文
共 50 条
  • [1] A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
    Nakano, Kenji
    Marshall, Shoko
    Taira, Shinichiro
    Sato, Yukiko
    Tomomatsu, Junichi
    Sasaki, Toru
    Shimbashi, Wataru
    Fukushima, Hirofumi
    Yonekawa, Hiroyuki
    Mitani, Hiroki
    Kawabata, Kazuyoshi
    Takahashi, Shunji
    ORAL ONCOLOGY, 2017, 73 : 21 - 26
  • [2] A comparison of cetuximab-containing regimens for recurrent/metastatic squamous cell head and neck carcinoma: the clinical significance of weekly paclitaxel and cetuximab
    Nakano, K.
    Marshall, S.
    Taira, S.
    Sato, Y.
    Tomomatsu, J.
    Sasaki, T.
    Shimbashi, W.
    Fukushima, H.
    Yonekawa, H.
    Mitani, H.
    Kawabata, K.
    Takahashi, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Weekly Paclitaxel plus Cetuximab in the primary treatment of metastatic/recurrent squamous cell cancer of head and neck
    Taira, Shinichiro
    Nakano, Kenji
    Tomomatsu, Junichi
    Marshall, Shouko
    Takahashi, Shunji
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma
    Risa Motai
    Michi Sawabe
    Shigenori Kadowaki
    Eiichi Sasaki
    Daisuke Nishikawa
    Hidenori Suzuki
    Shintaro Beppu
    Hoshino Terada
    Nobuhiro Hanai
    International Journal of Clinical Oncology, 2021, 26 : 1188 - 1195
  • [5] Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma
    Motai, Risa
    Sawabe, Michi
    Kadowaki, Shigenori
    Sasaki, Eiichi
    Nishikawa, Daisuke
    Suzuki, Hidenori
    Beppu, Shintaro
    Terada, Hoshino
    Hanai, Nobuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (07) : 1188 - 1195
  • [6] Activity of weekly paclitaxel−cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors
    I. Pajares Bernad
    J. Martínez Trufero
    L. Calera Urquizu
    R. A. Pazo Cid
    A. Cebollero de Miguel
    M. J. Agustin
    M. Lanzuela
    A. Antón
    Clinical and Translational Oncology, 2017, 19 : 769 - 776
  • [7] Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Greenhalgh, J.
    Bagust, A.
    Boland, A.
    Fleeman, N.
    McLeod, C.
    Dundar, Y.
    Proudlove, C.
    Shaw, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 49 - 54
  • [8] Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors
    Pajares Bernad, I.
    Martinez Trufero, J.
    Calera Urquizu, L.
    Pazo Cid, R. A.
    Cebollero de Miguel, A.
    Agustin, M. J.
    Lanzuela, M.
    Anton, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 769 - 776
  • [9] Weekly cetuximab and paclitaxel combination in metastatic/recurrent squamous cell cancer carcinoma of the head and neck (SCCHN): Clinical experience of a single institution
    Diaz de Corcuera, I.
    Serrano, C.
    Perez, J.
    Quispe, I.
    Arguis, M.
    Munoz, E.
    Benavente, S.
    Martinez, P.
    Parera, M.
    del Campo, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Takeshita, Naohiro
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Wada, Akihisa
    Sato, Masanobu
    Tanaka, Hideki
    Tanaka, Nobukazu
    Onaga, Ryutaro
    Hoshi, Yuta
    Sakashita, Shingo
    Ishii, Genichiro
    Tahara, Makoto
    ORAL ONCOLOGY, 2023, 147
12345